<SEC-DOCUMENT>0001739410-24-000114.txt : 20240808
<SEC-HEADER>0001739410-24-000114.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808080547
ACCESSION NUMBER:		0001739410-24-000114
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rallybio Corp
		CENTRAL INDEX KEY:			0001739410
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851083789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40693
		FILM NUMBER:		241186164

	BUSINESS ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203- 859-3820

	MAIL ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rallybio Holdings, LLC
		DATE OF NAME CHANGE:	20180502
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rlyb-20240808.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f0cf6e0a-a8dd-4547-bc6e-564a0162e89d,g:ca00bae5-2b7f-4200-ad0c-7f530abd5db5,d:d9d077b795b44612971a24b371d40477-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rlyb-20240808</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001739410</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-24">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rlyb-20240808.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-08</xbrli:startDate><xbrli:endDate>2024-08-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id9d077b795b44612971a24b371d40477_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 08, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">RALLYBIO CORPORATION</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40693</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">85-1083789</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">234 Church Street,</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 1020</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">New Haven,</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Connecticut</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">06510</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">203</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">859-3820</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">RLYB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-21">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id9d077b795b44612971a24b371d40477_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2024, Rallybio Corporation issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="id9d077b795b44612971a24b371d40477_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rlyb-20240808xex991pressre.htm">Press release issued by the Company on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rlyb-20240808xex991pressre.htm">August 8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rlyb-20240808xex991pressre.htm">, 2024 regarding financial results for the fiscal quarter ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rlyb-20240808xex991pressre.htm">June 30</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rlyb-20240808xex991pressre.htm">, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id9d077b795b44612971a24b371d40477_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RALLYBIO CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Jonathan I. Lieber</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan I. Lieber<br/>Chief Financial Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rlyb-20240808xex991pressre.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie352633ae42b46e0ab3e1f3a2bbc70d2_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit 99.1</font></div></div><div style="margin-top:12pt;text-align:center"><img alt="img96626370_0.jpg" src="img96626370_0.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:158px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#822;  On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024  &#822; </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#822;  $88.6 Million in Cash, Cash Equivalents, and Marketable Securities as of June 30, 2024 Provides Runway into Mid-2026  &#822; </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">NEW HAVEN, Conn., August 8, 2024 -- </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Rallybio Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> (Nasdaq&#58; RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported second quarter financial results for the period ended June 30, 2024, and provided an update on recent company developments. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We are working expeditiously towards the initiation of our Phase 2 dose confirmation trial for RLYB212 in pregnant women at higher risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT), which is on track for the fourth quarter of 2024,&#34; said Stephen Uden, M.D., Chief Executive Officer of Rallybio. &#34;Recent data from our large-scale genomic analysis of FNAIT risk across a broad population of diverse ancestries provides the first clear evidence that the proportion of pregnant women at higher risk for FNAIT each year has been significantly underestimated, giving us even greater urgency to bring RLYB212 to this underserved population that comprises a market opportunity of more than $1.6 billion. We look forward to providing updates as we continue to advance our RLYB212 program with a team of highly dedicated investigators who share our mission to prevent this devastating disease.&#34; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">Recent Business Highlights and Upcoming Milestones&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:107%">Corporate Updates</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">In April 2024, Rallybio announced a collaboration with Momenta Pharmaceuticals, Inc., a Johnson &#38; Johnson Company, to advance complementary therapeutic solutions for pregnant women at risk of FNAIT. Rallybio received an equity investment of $6.6 million, before deducting offering expenses, from Johnson &#38; Johnson Innovation &#8211; JJDC, Inc. In addition, Rallybio received an upfront payment of $0.5 million related to the collaboration and license agreement with Johnson &#38; Johnson.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:107%">RLYB212 Program</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">Rallybio remains on track to initiate a Phase 2 trial in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT in t</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">he fourth qu</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">arter of 2024. The primary objectives of this trial are to assess the pharmacokinetics and safety of subcutaneously administered RLYB212 in pregnant women. Secondary objectives include assessments of pregnancy and neonatal outcomes, and the occurrence of emergent HPA-1a alloimmunization. Administration of RLYB212 will be initiated by Gestational Week 16 and continue every 4 weeks through parturition.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">The Company reported top line results from an epidemiological analysis that provided the first clear and robust evidence quantifying the proportion of women of non-Caucasian ancestries that carry the genetic markers for higher FNAIT risk (HPA-1a negative, HLA-DRB3*01&#58;01 positive). These data indicate that the proportion of pregnant women at higher risk for FNAIT each year has been significantly underestimated. Specifically, in key geographies of North America and major European countries, it is estimated that more than 30,000 pregnancies each year are at higher risk for FNAIT, representing a 40% increase from prior estimates. Full data from the epidemiological analysis are expected to be presented at a scientific conference in the fourth quarter of 2024.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Screening in the Company's FNAIT natural history study is ongoing, with more than 12,000 pregnant women screened as of August 1, 2024. In the third quarter of 2024, Rallybio will begin to transition European sites from the natural history study to the Phase 2 trial, where sites will continue to collect natural history data in women who are not administered RLYB212. North American sites will continue to screen pregnant women in the natural history study which will be progressed in parallel with the Phase 2 trial. The totality of natural history data from both studies is designed to provide a contemporary dataset for HPA-1a alloimmunization frequency in a racially and ethnically diverse population that can serve as a control arm for the planned Phase 3 trial. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Several presentations and publications are expected in the second half of 2024, including additional data from the Phase 1b proof-of-concept study and the rationale and modeling that support the RLYB212 Phase 2 dose regimen.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:107%">RLYB116 Program</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">RLYB116 manufacturing work is progressing and is on track to be completed in the third quarter of 2024. Drug substance characterization data indicates that Rallybio's efforts to enhance the manufacturing process have been successful. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">Additional complement biomarker analysis for RLYB116 is ongoing, with full data expected in the fourth quarter of 2024. This work expands our understanding of the results of the Phase 1 multiple ascending dose (MAD) study, which was completed in the fourth quarter of 2023. Based on these analyses, Rallybio believes that there is an opportunity to pursue indications beyond generalized myasthenia gravis (gMG), including paroxysmal nocturnal hemoglobinuria (PNH) and antiphospholipid syndrome (APS), at doses tested in the Phase 1 MAD study.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">The Company will provide an update on future plans for RLYB116 later this year. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:105%">Preclinical Programs</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In accordance with its 2024 operating plan, Rallybio is advancing its preclinical programs to important 2024 milestones. Beyond achievement of these milestones, Rallybio is seeking alternative options to further advance its preclinical programs, including partnerships and other forms of non-dilutive financing.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:105%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:105%;padding-left:14.15pt">RLYB332&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:105%"> Presentation of nonclinical data demonstrating favorable tolerability, dose-dependent pharmacokinetics, and sustained pharmacodynamic effects with RLYB332, a long-acting version of the RLYB331 anti-matriptase-2 antibody, is expected in the fourth quarter of 2024.  </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">ENPP1 Inhibitor, Exscientia Partnership&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Rallybio and Exscientia expect to achieve development candidate nomination of a small molecule inhibitor of ENPP1 for the treatment of patients with hypophosphatasia (HPP) in the fourth quarter of 2024. In addition, data from an early lead compound in a nonclinical model of HPP will be presented at the American Society for Bone and Mineral Research (ASBMR) meeting which is being held from September 27 &#8211; 30, 2024 in Toronto, ON, Canada. </font></div><div><font style="color:#ff0090;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Second Quarter 2024 Financial Results</font><font style="color:#ff0090;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%"> </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Revenue&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Revenue was $0.3&#160;million for the second quarter of 2024, compared to no revenue in the same period in 2023. The increase was related to Rallybio's entrance into the collaboration and license agreement with Johnson &#38; Johnson in the second quarter of 2024 and the recognition of revenue related to the collaboration's performance obligations.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Research &#38; Development (R&#38;D) Expenses&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">R&#38;D expenses were $12.9&#160;million for the second quarter of 2024, compared to $13.1&#160;million for the same period in 2023. The decrease in R&#38;D expense was primarily due to a decrease in payroll and personnel-related costs, largely offset by an increase in development costs related to RLYB212 and RLYB116.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">General &#38; Administrative (G&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> G&#38;A expenses were $4.4&#160;million for the second quarter of 2024, compared to $7.0&#160;million for the same period in 2023. The decrease in G&#38;A expense was primarily related to lower payroll and personnel-related costs, largely related to the workforce reduction and lower ongoing headcount in 2024 as compared to 2023, and reductions in consulting fees, director and officer insurance premiums, professional fees and other G&#38;A expenses.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Net Loss and Net Loss Per Common Share&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Rallybio reported a net loss of $16.2&#160;million, or $0.37 per common share, for the second quarter of 2024. This compares to a net loss of $18.6&#160;million, or $0.46 per common share, for the second quarter of 2023.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Cash Position&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> As of June 30, 2024, cash, cash equivalents, and marketable securities were $88.6&#160;million. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Rallybio</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rallybio (NASDAQ&#58; RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs&#58; RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">www.rallybio.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and follow us on </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LinkedIn</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Twitter</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on our management&#8217;s beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the timing of initiation of the Phase 2 dose confirmation trial for RLYB212, whether the results of the FNAIT natural history study and the planned Phase 2 dose confirmation trial will be sufficient to support design and implementation of a Phase 3 registrational study for RLYB212, whether the manufacturing work for RLYB116 will result in improved tolerability, if and when tested in a clinical trial, our expectations regarding the usefulness of data from our clinical studies, our expectations regarding driving awareness of FNAIT through the Johnson &#38; Johnson collaboration, our ability to more accurately identify the number of pregnant women at higher risk of FNAIT based on the results of the epidemiological analysis, our estimates of the market opportunity for RLYB212, the timing of publications relating to FNAIT and RLYB212, whether our conclusions from the RLYB116 biomarker work will be informative, the timing of achieving milestones in 2024 for our preclinical programs, the timing of publications, the likelihood that Rallybio will be successful in developing RLYB212, RLYB116, or any of our other product candidates, our ability to successfully identify and implement alternative and acceptable options to further advance our programs, our estimates of our capital requirements and the sufficiency thereof, and our cash runway. The forward-looking statements in this press release are only predictions and are based largely on management&#8217;s current expectations and projections about future events and financial trends that management believes may affect Rallybio&#8217;s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">history study, and the Phase 2 clinical trial for RLYB212, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio&#8217;s filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2024, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie352633ae42b46e0ab3e1f3a2bbc70d2_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Tables</font></div><div id="ie352633ae42b46e0ab3e1f3a2bbc70d2_7"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RALLYBIO CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SELECTED CONDENSED CONSOLIDATED FINANCIAL INFORMATION</font></div><div id="ie352633ae42b46e0ab3e1f3a2bbc70d2_10"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FOR THE THREE MONTHS ENDED JUNE 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FOR THE SIX MONTHS ENDED JUNE 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share and per share amounts)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and license revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,946&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,130&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,882&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,332&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,953&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,125&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,334&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,083&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,121&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,457&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,035)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,083)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,822)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,457)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,729&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before equity in losses of joint venture</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,749)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,413)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,093)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,168)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on investment in joint venture</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,236)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,630)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,265)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,948)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.46)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.89)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,128,059</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,363,902</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,450,837</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,306,715</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,236)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,841)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,351)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,006)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="ie352633ae42b46e0ab3e1f3a2bbc70d2_13"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JUNE 30,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,<br>2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,614&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,929&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,431</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,620</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,414</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,436</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,017</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,184</font></td></tr></table></div><div id="ie352633ae42b46e0ab3e1f3a2bbc70d2_16"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contacts</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investors</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Samantha Tracy</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rallybio Corporation</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(475) 47-RALLY (Ext. 282)</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">investors&#64;rallybio.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kevin Lui</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Precision AQ</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(212) 698-8691</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kevin.Lui&#64;precisionaq.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Victoria Reynolds</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Mission North</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(760) 579-2134</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">rallybio&#64;missionnorth.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rlyb-20240808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f0cf6e0a-a8dd-4547-bc6e-564a0162e89d,g:ca00bae5-2b7f-4200-ad0c-7f530abd5db5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rlyb="http://rallybio.com/20240808" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://rallybio.com/20240808">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20240808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20240808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://rallybio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rlyb-20240808_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f0cf6e0a-a8dd-4547-bc6e-564a0162e89d,g:ca00bae5-2b7f-4200-ad0c-7f530abd5db5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_840a17a3-bddf-492d-b984-991cf3c30662_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_79b51473-8aaa-4523-be33-acbde247246a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_ff28ff03-48a0-4592-a7a7-0e62a63a29e8_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e94bf0be-d98f-4ca8-a1ed-fef9c018db9d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_19ef572d-fad2-4526-98b8-d26e6acf63e2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_45ee2c4e-5daf-4469-bf80-7e0f329bbc4d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c2256bdf-77c4-49aa-8981-527d0b9446db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b3618a30-0e27-4993-bb39-715f675f9706_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c62532ca-1548-412d-be5c-a7bae8ccaa9a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d1341126-e5d0-4c0c-a2b4-f781115d3095_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_04324cd6-118d-40db-a7a3-6c8557facf3c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_1262f987-7b4d-4dc4-8086-6ba7c949567e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4979a278-357b-45d4-b9dc-0661bf48661a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_988b2b67-9272-44b6-852f-e9cfb82c2a36_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f1ea50f8-0452-4475-b8c2-8a0cf67e638c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_aa0e7fda-9f28-4e29-94ec-078240d640f8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ccfcb540-06d6-4d3b-b48e-732041d461f5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_ac224f18-9ee7-4bf6-b424-36c58321f2e6_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_28a082b5-2d64-41ff-a235-3cd5fbe831f6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_32efb500-ba92-4373-b9de-cb256515573f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6e8d0012-159a-45e1-a5ed-360e67e0f7c2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fb21bcae-409f-4756-b61b-3e3b03ea5a0b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6b3638fb-2a4f-42ea-abd4-2aab6610d329_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_17057c21-8cb1-454b-9ddb-50ef84b39401_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rlyb-20240808_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f0cf6e0a-a8dd-4547-bc6e-564a0162e89d,g:ca00bae5-2b7f-4200-ad0c-7f530abd5db5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rallybio.com/role/Cover" xlink:type="simple" xlink:href="rlyb-20240808.xsd#Cover"/>
  <link:presentationLink xlink:role="http://rallybio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_15104b8f-e2c5-450a-a95e-11a0dd51465f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_DocumentType_15104b8f-e2c5-450a-a95e-11a0dd51465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7eb11d1c-e227-41fc-a5cf-29d2b1cb8c61" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_DocumentPeriodEndDate_7eb11d1c-e227-41fc-a5cf-29d2b1cb8c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_54f7d0d4-60e3-4feb-8574-30698f25c52d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityRegistrantName_54f7d0d4-60e3-4feb-8574-30698f25c52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_12a839e6-3a10-409c-be20-c6b6a7991a45" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_12a839e6-3a10-409c-be20-c6b6a7991a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ff26c07a-5e5d-47a0-98f1-ee3ee5348725" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityFileNumber_ff26c07a-5e5d-47a0-98f1-ee3ee5348725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5006fb3d-b8c7-40be-b0a9-39e16cdc4b7a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityTaxIdentificationNumber_5006fb3d-b8c7-40be-b0a9-39e16cdc4b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_521c8c59-4d84-4908-984c-0e72725e1048" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityAddressAddressLine1_521c8c59-4d84-4908-984c-0e72725e1048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_759dab80-2109-4679-aa59-8fcd468d4118" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityAddressAddressLine2_759dab80-2109-4679-aa59-8fcd468d4118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9d39227a-44c6-4318-902d-8f536b288d76" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityAddressCityOrTown_9d39227a-44c6-4318-902d-8f536b288d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c6fce609-d279-42b7-956d-f5ca90896150" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityAddressStateOrProvince_c6fce609-d279-42b7-956d-f5ca90896150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_672bb303-8637-4cf5-88b5-e9c08cdaeb93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityAddressPostalZipCode_672bb303-8637-4cf5-88b5-e9c08cdaeb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5ee144cc-155d-4c47-86eb-18f2e065a36b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_CityAreaCode_5ee144cc-155d-4c47-86eb-18f2e065a36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a52fef5c-e74f-497e-a2f1-b769da144b13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_LocalPhoneNumber_a52fef5c-e74f-497e-a2f1-b769da144b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_1864c105-63c4-451f-be07-11f7fc62bd75" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_WrittenCommunications_1864c105-63c4-451f-be07-11f7fc62bd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_9a3038f2-33a7-4df8-bcfa-4b6d09d3f8b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_SolicitingMaterial_9a3038f2-33a7-4df8-bcfa-4b6d09d3f8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_613f827a-4040-4d65-b29b-aae0aead8bc7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_PreCommencementTenderOffer_613f827a-4040-4d65-b29b-aae0aead8bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_b54f17d0-a867-479d-ad97-27301fd5934e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_b54f17d0-a867-479d-ad97-27301fd5934e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_28ed79b6-a61d-4095-a79b-16f5b8bd32b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_Security12bTitle_28ed79b6-a61d-4095-a79b-16f5b8bd32b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_01ffde67-f8bc-46da-b5db-25ba697f41bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_TradingSymbol_01ffde67-f8bc-46da-b5db-25ba697f41bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a8379e70-0970-4e38-a856-432cac21ec2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_SecurityExchangeName_a8379e70-0970-4e38-a856-432cac21ec2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2d0ab743-c046-4e4b-9c8b-a29cdbc3187a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityEmergingGrowthCompany_2d0ab743-c046-4e4b-9c8b-a29cdbc3187a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b451c486-e731-4050-8a76-b426087d4ef9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityCentralIndexKey_b451c486-e731-4050-8a76-b426087d4ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_153112e3-02e7-4eea-9174-3e72984311e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_AmendmentFlag_153112e3-02e7-4eea-9174-3e72984311e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_3cac2ef5-ec09-46a5-aaaf-0eebaa1f5e7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5cde5958-1d6f-4818-8ef1-c7977131986b" xlink:to="loc_dei_EntityExTransitionPeriod_3cac2ef5-ec09-46a5-aaaf-0eebaa1f5e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img96626370_0.jpg
<TEXT>
begin 644 img96626370_0.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  M )L# 2(  A$! Q$!_\0
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MV,]0&V#N/< QQRZL?S![9,3<<;?P[EP/@<#C<//"*-'ZKOB!-1#52]UK!O\
M2U#NE%)%B-$6UHB#MZ[:IF,H)(&'GV*4C,QA2E$B:\:[D$G)2B5)VJ?'%#<_
MG^<PJ+H* MR_1@[5WWM_4M3M+B5$[MRV:+53$'CH\D+'3U#5%T*TK4\#)H2A
MWRK+H9S#-\Q6!!NJW4!0A\(:@SK'%E8$\@XF2*>V@-7]XI4'DTOENB18KGI>
M"Q-6+'<>HX!/'RO]^CCVM25EH32+J5EX62D(:5CK(W'>1LI%O7+"18.F]-O3
MHNV;UJ=%PU=(G^I)PW5352-@4S@.! %OPUMR;BW"L=JG=U]7U;5R[B[AT&C&
M.:RJN=J=>.17MTR6618.)Q^_59(JJX5630.F110 4.4QM^";U5<*J;L\H^;N
M;7#Y"2K&O]$CJKJH?MF:4>@]GIRV@2$D[28H"*+0B[M914K=(?32ZQ*7Z<
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MA@ R503!@=]AP.! =\Y$1#8!\<5!,](9SG(YR.1[CYP&WL& P&WCA9B+UO\
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M8#(?J30'CO\ \M6&0$<><=O_ )P3"GU #DF1!Q$F T M,F$X=( %JTBX$P[
M&/?(!C'N' R_A?E"&L'JWZ%$U,7(M^(]"A#](?IHQ !$2B8-QS@,9']]N*L7
M_$_$0NS_ !C%KYUDO]?K\^W;I#A9;XIQ?R\PZC1\,]_BKU8 /3T_I2@ B&0#
MZKGQP8 1\#GMW\;8XK/B#;$5!IYU86/UU6O0-&K5J_A$I=ZT+Z"3.[]JEF\O
M3KQT= >LA:IIIN1B_54%,7*<6+8HG$YN/.^&=53-JMU7%(HF<0M.D(@10A]@
MNC%@(CT"([9QG'G #GACKFAZ6T-7>BN\MKF[5->L(^"4K^W+@X&%1K7=$$5F
MX@J/2F=0?Q1N@^ASIE$H+B]2(J;HR V,S.7!^*HY)#]Q+CX>-D@GRF&;'B1]
MWI2FF/R4]$[ 3#U#*JGF^"!Z_6O^AT)3G-Z^J?KCE760D*!DBIN];R5)N3MT
M!*"[.D:9;1U67!9*E(J=5LLUJHE/PBR8AD43OFZW3@Q!G;R,-- :== %M)*4
M8_*5G?5TXO94WJ)E!PFQJI)LWHA@)A*50$$**8Q$D1!0,MW<S(@'W#PE!I?H
MFYVLN^6E#1]+RLH\I.(KR1IR'@E!$/R525050^KN[SE+8W2X;L6E0NNM7 )K
M-FK%,02(B0/IIQ43'0,3&0,,S2CHB%CF<1%L&I 1;,8Z.:I,F#5NF0@%20;M
M4$T$4R@!2)D*4H  <0?$,,>CZ?!H\+AOM.5/GRLO!:+=MQE84. FWY;H[KGH
M9/(@C'\Q+-R:]*H?L\<]+4\L6UU+3O.&YHMSIMBU=55;FLW,+2 NB +N%"NI
M)$L_+,RB/4FL]C8QK& X#<J!UDR&Z5C]3-F=@# ;9' @.,X#8,  "7< QC80
M !#8>%I-8"=R.5IS$93F'TS1$_7>E+4M#1='ZFHZF&PO9*BZF9E:HHU,NE@$
MVY53LVDS"N7*C:/>+DF89R[2>NF742Z*YP/+:E:(3KLFK*V+*./'#('A)1Z_
M85H@((F4".5HU9D$[^)[>B5FFU4.HH)2IF.40'C,U3'RLYL7,QHI<K'DQ,:%
M#"C2^#)#$L<L$@0,482!G\P 8/Y2:- RLVTCS JH%<T0 "#[<WT/#GC0;:V-
M_.6MJEHHJ,9=N$U&Q5M@?-4RI/)NF'JS6:09O_2 %'K:,<)2#=!-8%")H3CU
M(/H<F*/=SI_\8'*-$0+@-4 %# #C!:LH<I2@ !C8H 'N ^.P#C*AZTJGG/\
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MUEVD4LZ,J*PK'AFTNE&!]8@(I$;D;B( 44>C)1),),;@.-PVP.,B/MG& ]A
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140181876546880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RALLYBIO CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1083789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">234 Church Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-3820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RLYB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001739410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M]//3B%$P,OL W%]):=X;]FV_^%C3_P=02P,$%     @ MT (69^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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MH'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @
MMT (620>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ MT (60=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "W0 A9&-IK
M0N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " "W0 A9F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( += "%EZ,I(6>P0  +@1
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " "W0 A9GZ ;\+$"  #B#   #0              @ &_#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( += "%F7BKL<P    !,"   +
M          "  9L/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( += "%FJQ"(6
M,P$  "("   /              "  800  !X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4    " "W0 A9)!Z;HJT   #X 0  &@              @ 'D$0  >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "W0 A999!YDAD!
M  #/ P  $P              @ ')$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+
4!08     "0 ) #X"   3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rlyb-20240808.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="rlyb-20240808.htm">rlyb-20240808.htm</File>
    <File>rlyb-20240808.xsd</File>
    <File>rlyb-20240808_lab.xml</File>
    <File>rlyb-20240808_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rlyb-20240808.htm": {
   "nsprefix": "rlyb",
   "nsuri": "http://rallybio.com/20240808",
   "dts": {
    "inline": {
     "local": [
      "rlyb-20240808.htm"
     ]
    },
    "schema": {
     "local": [
      "rlyb-20240808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rlyb-20240808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rlyb-20240808_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://rallybio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rlyb-20240808.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rlyb-20240808.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001739410-24-000114-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001739410-24-000114-xbrl.zip
M4$L#!!0    ( += "%F R0[M%@\  -IK   1    <FQY8BTR,#(T,#@P."YH
M=&WM'6MWVCCV^_P*+;,[3<Z)C6W,,PES*$D[3-,D"_1T9K_,D6T1M#4V(\L)
M[*_?>V6;1P()I"20-/U2;,G2O5?WK2OEZ-?1P"?73$0\#([?F;KQCK# #3T>
M7!V_:W2:K=:[7^L_'?U#T_YXWSXC)Z$;#U@@25,P*IE';KCL$]EGY&LHOO%K
M2BY]*GNA&&A:\EDS'(X%O^I+8AF6G77+6D6M9[B]$C.H1BN>I]E%NZPY;HEI
MQ9)-#;-DL4K5.[BJN=0P',J*FN64>YIM&89&/</5RKUBP:".5_2<XH%7\ZJ>
M42X[Y6K1L>V2:57+)K5LIU V/=NPRV4U;U\"SH!W$-7X2![G^E(.:_G\S<V-
M/G*$KX?B*L\#GP<,<<Y+08,(4:(2B)0'- S-L#33RJ6#C"(^-\A-00T!,)KY
M/SZ?==P^&U"-!Y&D@<MRDZD7SVP99F%F^LDDT,Z7?6'@%_/#P_??[NF.S0Z-
MLNZ+X#>KU6I^A,3*QO38% (U7,1<_2J\SD,#TJ4P ?;.['-C8NN4#%*#8>8Z
M9\/>MPAF43,J6L%4X]1\"OR:8X'VI9.K'_49]>I' R8IP5$U]G?,KX]SS3"0
MP+M:=SP$O-WDZ3@GV4CF%9KY^D\__70DN?197?AC1T.6-2I&Y2B?O#S*)T,[
MH3>N'WG\FD1R[+/CG,>CH4_'M2 ,& # 1S7LR$3RDWL>"]1/:#\' 1+<3>8?
MR3;K'>=<#? (Z !'8KQV&L!TXR9 )ZC?"CPV^L3&.<*]XUQ/ RK7#6"M<J%J
MF\91?F[4-29I@!Q[*,L??'J5(PEMCW.P'K4>'S%/ZU$?^2.=U<[5U8L[$^;G
M,12LQP2H$!8M6!A<^%JDY % (HH1:A*6XS@7\<'01W94[_H"(9Y; WT4>;!"
M:K[I).F<41@+]:3$I):BK6!'M+/W3!$V>^(>/O<X$T3!Q!8R8;/U:9[@MS^N
M9Z_F1Q\">4(O>P+A%/($5&8=\4'61:ZZW38!TUO2-6O)GK-)\G-X9T2:4"4_
MPY!Y8-N$=Y$Z_"&-^1=2;_I-RN\#'FA]AFJ]9A>'\O"&>[)?,PWC7SG5KWX4
M#2DPA"-PQ9+?R2"3H>I'DCH^RT9T0@'@:6[H^W08L5KVXS 3K409:.JCPP$5
M5P""$TH9#FH( =@PR5WJ:]3G5T$-R9 V3X'3C01 "6207C9SVJQ#4_[N^VI%
MKQJ+FPS=5._S:CR1-:9T*0QE3GT#F" !CG.@'N>13<&'GL0+8R3&SP#AX9!Z
M:']K!C%AC&R"O,)\T5HDM)#A4!%"89X0P06.9"*7+$;6'< )10TGPKEZP#$@
MZ0/NCVOONGP 8GO.;D@['-#@W4$$2A>TL^"]I&/$_\=J9@5F48\W":9E&$>M
M38JY:2&5OYRWNJ<GI--M=$\[\SPP _RN0-LY;7YIM[JMTPYIG)^0TS^:OS7.
M/YZ2YL7GSZU.IW5QOD44K)50^-KH_-8Z_]B].#\@)WI3!X>K:%>W"+9Q"VQ[
M(=A_/>K?4K1FI$$!L"L,]N&B_9FL;ITS1SOQ51(;#)JXHGVZ:X#?%G@7Q _T
M1_OTO$O:IY<7[>Z+ _\R%E%,(;*3(>DP%[UL8A9(*(A9W//V2=A381XTQ8)+
M#A.?CMP^>'>,-%R)S6:U8*^"=NE9L+[-FXNQ1F<*86^S82@DV<N>&05WBD62
ML&N,=H5J9MY^[1$B?*E\M-/$<YMWM#UXHPU@B#Y^IGETK(UA:HT%$[\[5V_$
M5S% 8E0.5 C])O_/RTF6O1(GK1O=M=D5CS"JE>?0DBTWQ';MQMG9G^];%^!Z
MM$&3-+K*]UAQS6>(4W@.XI17HLW>Z8B"CD 2),*6H4YH1#I#YF(<Y1$>D):,
M2+,/X1 3^S\V8^=>2'Q4L'2K4+@W/MK64/8J4=NR$"T+PJSA",.PNZ)TFZ()
M,9_?CAF/T3ZMP T%V#253>M(,$/-, ZD&#=#;]Y&87(.,Q22#45XC>-,C9,-
M!I3Y](:*!6FAE,NE]V-2^ /W&71V0#NEU"IB&LG4;*-4+;R1ZQ:YNG342C-J
MKF+*>=J5(/0I:J91*90KU7N)]S+$^K;=O&-@%!'WE&2B#WX!OK<@OX/K'7E<
M.><JM0;&=$Z2]Y^"C\ @;0G]9C@8\ BWI@B*$TEXXDF0W.HRM]H=<CH8^N&8
M";6N\Z) SD-]?Q&3W\HXFL5[4HYWDHJ;[;:BV*TX[()E\UGOCA,S6;2M.H>;
M48 -SQ,LBM+_SF \,U-^Y5P=G!GPBV/A]DE'"L;DP3(EN"*N#<&I_WT8DC6G
MW#'R6AEY*[EZ)^:@9TW#NKN?]D;6%<C:A)\7HAO>3%S#:JZ.(/U&KUEPAU?7
M2*+,3:/,X86X!$>4JZWN%?U4T\C5FV$08%K+C>7]T?3N6Y6G7<O+$*CH_X</
MDU @I: )SFNIN&"_^1&^U^.-P [:[I1JF->X%,"5?$A]<CIBP&?\FI&+'EAQ
M%KT^GP48A""'+'!,5MFIW*4D\#0?]<O/%<LL'T:DRWPV[(=!YG,>H)_MQ[@^
MI"$85:C7GD=3+TX^;<M,K)GL1,N !)M3)A8X-,;2&/B-FDNI>1:"]%\B7\Z'
MQV8!X^.J5J@L]V#NW8FR=BA9_ &,.@2[YRI;+$CZF.K9 \)[F"$.KIA'.N@%
MD#,:R70#YRUGO V<FGWF?E.[@W0(SM<0?&#PIIUP1!SFAS>X8MB("TDJVB?2
MXS[J41X1CB5X'JRD#$G$![$O:<#"./+')(+0-^J-U9?I!Z$#ZY=$Q.ENI)CN
M),0PCB T&&=MO="'R?$[= @Y9A&BVBM+OI?T:N'^VJ15WUMZJ5S92.J]4M:K
M56L3J??-)@O62F-]A8%Q\.C1DK&F"_Y5< FR@!FO.$CS/M&#59FFG:N'F\TE
MWYMG>6;MHFB84@;0F"4-&<[4*[1C$%7;*J9*X%:= I8G[)EETOS0)E;!T*'C
M*MFT^^KW7F,R;;?EHQ/ZW(7U#*X^@W'!+,O#PE%\_<(Q)0L9I'2Y*QFF3<'G
MGA&.N<J=B6C8H)Y5SS?I>&G2<2D86@ZLB%=%@^A4B8M>#R.$AZ2D]/JE!,BC
MN3/T>="6F+:G67O._FHRD_1]DYH7+C6M*(J96$MVRF^R<U=V"DRS]]S59"?M
M^\@DXL(LZ9:2B#,.9Q*5,@%Q[7!15:W2+&F4"A1Y;4%IH:I7C.I&HE)PUHW2
M1J)2LZ0;UKJ3/S500*E2\?ZH^V64LZRX(]7%0Y1)>;7;)ZY/HV@-;?DRMHU6
M)86@"*VJ]NB,!T[H[ZVU2?2JB'&>%@8KMF"9L0!5>=/G\&:J3]?9;4S58VHG
M2 21DC=_OF[7B//=,7)B@L:FY2A)F[@I%=S^'@R H!T9NM\.R) *<DW]F)%_
M*A5ODB$>@NU_7R'G SSYXRU(*N2)?$]6HYJKM\_^?/\B"/T$M7\/4]FT'\7V
MF9>9G*>X71J":F6^*L0R0/,T.B>-?Y./?NA0'SPT'WPT\IF*;VQYE<BZ^]Q;
MVI5I!1XZZ8PX8^*J'1H ZQNH5*9J26]MG_"( (C@X2/D5^1*A#>RC[[^$+=4
M:$0\UH,IU"&-)-UJ%!><"9L>!2N0O5]^-DOE0]Q3+U0/5>8U^P9F@[4:XBD/
MW.)+X@;+T:P5CYG='AM#B>GG,Z/KN[US=KJ$WFON1G]_Y/RH(TP9]!\5\,T$
M]D5!LQ3Q]"(),U<?/6:/>HN2U+M'-@Y (A8*&K^S1=D',5(:!L0H"%5,&$=,
M]0(ZIQNA>,\)5W%B<K<#DE/-Y8]Q<G7?#K)( +A!BV#7/(+O0#AIX&+ZE[HN
M'N7 SG@CC$>%%R5;H-ZR@+2P1R<!Z:RXZ2^%$4?="=F2TY8/WV=BW9>Z>;NC
M8L-W5,S>%3(,DY6J">93+)*[<WO(% 0UMS']A#K@S<3R[B</73BR[JTGY<FM
M)WTQ=;^NF.8(1K]IM ?6I4;]&SJ.$/O-7HVRI$)G2YFMEF0#8NF&1=HLBGVI
M:ATO0#NE&4#0,>3#1/TT0U"'V+"2Z7T6M!8KF8N I">KTX/5!Z1-?7_L\!"0
MF!RI <\HBD%Q4M"A6.<)3,LH:&T:!*!F757( B29ZE^1$@GU-BK4OV-UG)4D
M^OWW.&"D8"0SZJ0!DC><E*S,SP!N3"\6 8_Z.#TZ0GWN<$FJ5=U$]:T<G68L
M!&9ETP/L>%(F+;.9*N\=78 N8,R#R9U>2LW3S,><,EWFTBW'E.SQ27'F+)'V
M,:+U?65K'08>+)APCZ#/: %>W&>>^FT>JK4"RPAJABGNGEC&RHH.Z0$N$!TD
M:[QWVXXJ)S=$M_L&C#6)8N>_&&>H-63$Y]3A?C*VFHU"S)8 < "PBQ0+/HL$
MGYSZ@@?P.R878B'MT#U(2Z:6%D1D3GIX-T-_@"D8-E2'L]E(\2368S&)9 +O
M Z:+DC/;[OR\4>R";Y).O4#\5[QOREATX13&<!K82T%=68OB ;#P^'"']&-5
M-\P9+:A.*N!V2:(>4ZZ,5M:)F7W5<#^H9A;TR<U.X&W"L#4M>;<ET=WS]K=7
MK7N+-GK%1CID)'ZI/IQI[N &1:6DF^7[3^0_?H-BY[8Z,]MQ'NK/DHG?.0*<
ML,@5?*B.%S]UIOV[RP4VBCFZ"UM.P#YTP'4I87J])R-, I_'W-09KBE_ GL!
M3'2A;6:)$!UN'4"RX [1$1M5JZ9R:033^W*@ZAOF?&[E[#M)W7F:TD)?\RA/
M7PO&6=3SBE!*PBG,M5&APH#EX5B/1R!?MZ*R5T2*-,!\11AEUY[110=U-^M^
M;,\ F8;]8_H<S1"@(9<48L\6[D "A^*YV1,J:7+IQQX;.,SSTKOF(<Q$*6XI
M)YVH.^F]])Z]=8K(7EP^$D_X[5Q"<G>*[UH?SQO=+^U[+AK>C9S7["V;R>[0
MWS$7::9@U533@FTE+_;'Q*4Q;@6I;%ER8R5.XT#H"PL$#9C,A&D<UJ=^+_-Q
ME#I..V"&BL4!?*3&H['LAP*P\];)Y;Z(:+NJ&\7U@NJE-7RV7MQ4.:!>K&YF
M)+NBVW;Y&<_@;;;;;MFMQ35KBZ_I?/ $P#;O:-KL28'=6J0E"0TJI[<TO)*"
M_/E-J]>#G+*/[\>O:+D41ODH3WX/ RK!D).63LXX<YAXPFMS-M-M\RFL;1!_
M >'1RVWV.>O-[-8DE_0(M573!7<ZBL6B)=KU:"*?_%DB];>,ZO\'4$L#!!0
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M:%MDI%.J>_ DO#I2=SZBVNZ@OL@-L^U%G9-CGY.I3DM#CJ6V@XY])M5IJ^5
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M&0XZ,4J-LPW3-IGW;8[C8,'%RHDR/C$$1RWV!",EML.3V_ZA?_LNTS@VFM-
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MK!PL2P;@,J@Z7=>S[QVJ7(^<J @4"0G!35!\']RPO7,>^_SO'W_H](Y(2E\
MWS /[B3E'"=\*!B F0AO% (HPRGSU'C"PRE+(I@X ,#!4,>>!*++@?08]Z]
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M*CP-')&":(#4)'*,;K?%AO(*V2:- 02X>4CN>,120$'H(0/!TO"&C ]0Q$>
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M^5\PY6D*, I G ?*F_ &(R28*<@GT.LIXDFW90'SY5H#)RA 1OVV:F46\@\
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M][T_GK]]02*.*83)2,7P_T!"X,CB:>B#G0+<''^\Q,J,A% %"X"HL\!(AEE
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MR]?O+UZPL1 DOWG!9E_@UY$(? WEI9@D8MS'MHC]O'8EKS@'8#\IK$Q1%ON
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MK+9E1/ZON)(A>Y?*!X7B8R0\&0-3L>,_'I:O'-MYP;H'O4:O>V _*#,199I
M&6*F288A_O=2?JJ"37LO?,D?BGRV Q#\4WH@?I*S"S$-P;?<EGE=#LU[&1-/
MGZLH&3TH)'O[W=8+UMD_:#BVVWXHMB90,JU(7#W6& H1066VWAYFEBK@:GD_
M/_>5/X5_1LDX>/7_4$L! A0#%     @ MT (68#)#NT6#P  VFL  !$
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M(P  <FQY8BTR,#(T,#@P.'AE>#DY,7!R97-S<F4N:'1M4$L%!@     %  4
*4 $  )I$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>rlyb-20240808_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rlyb-20240808.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001739410</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">RALLYBIO CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40693</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">85-1083789</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">234 Church Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 1020</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">New Haven,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">06510</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">859-3820</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">RLYB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-22">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
